AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23382637
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL 40% wt/vol barium sulfate suspension before 3 mealtimes, 60 mL 60% diatrizoate meglumine diluted in 250 mL water after supper, and 10 mg bisacodyl enteric‐coated tablets 1 h before oral administration of 2 L PEG‐4000 electrolyte solution (Study Group A)
Trial: 23382637
Drug: Identical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical treatment to Study Group A, but bisacodyl was given 1 h after oral PEG‐4000 (Study Group B)
Trial: 23382637
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group managed using the same strategy as Study Group A, but without administration of bisacodyl
Trial: 19214123
Drug: Saquinavir/ritonavir (SQV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir/ritonavir (SQV/r) 1000 mg/100 mg twice a day
Trial: 19214123
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) 400 mg/100 mg twice a day
Trial: 17626759
Drug: Shenqi injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenqi injection after operation
Trial: 17626759
Drug: No immune
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No immune supportive treatment (Control)
Trial: 11718454
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation with beta-carotene (6 mg), vitamin E (30 mg), vitamin C (120 mg), selenium (100 microg), and zinc (20 mg) for 2 years
Trial: 8483620
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil (5 mg/kg twice daily for 10 days)
Trial: 8483620
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V (13.4 mg/kg three times daily for 10 days)
Trial: 26505570
Drug: Ropivacaine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (10 mL, 75 mg)
Trial: 25391305
Drug: B-vitamin group
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: B-vitamin group (400 µg folic acid and 500 µg vitamin B12 daily)
Trial: 12888775
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of encapsulated dried leaf
Trial: 12888775
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of encapsulated dried leaf
Trial: 12888775
Drug: 1600 mg
RxNorm normalized name: glycerin 1600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1600 mg of encapsulated dried leaf
Trial: 22959103
Drug: L‐CRA (Laser-induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐CRA (Laser-induced chorioretinal venous anastomosis)
Trial: 19179968
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alfa-2b monotherapy (1.5 micro g/kg/wk for 48 weeks)
Trial: 19179968
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (pegylated interferon alfa-2b + lamivudine 100 mg/d)
Trial: 17401588
Drug: Non‐self‐tapping Ankylos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non‐self‐tapping Ankylos implants
Trial: 17401588
Drug: Self‐tapping Camlog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐tapping Camlog implants
Trial: 11219481
Drug: Extended-release clarithromycin
RxNorm normalized name: clarithromycin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release clarithromycin (two 500-mg tablets once daily for 7 days)
Trial: 11219481
Drug: Amoxicillin/clavulanate (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (one 875-mg tablet twice daily for 10 days)
Trial: 11219481
Drug: Extended-release clarithromycin
RxNorm normalized name: clarithromycin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release clarithromycin
Trial: 8287747
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein level higher than 2.5 mg/dl (Group A)
Trial: 8287747
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein level lower than 2.5 mg/dl (Group B)
Trial: 27234409
Drug: Talactoferrin (TLf)
RxNorm normalized name: Talactoferrin alfa
DrugBank: Talactoferrin alfa (DB05426)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talactoferrin (TLf) administered twice daily by gastric gavage from day 1-28 of life
Trial: 16897910
Drug: Computer-administered survey
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-administered survey
Trial: 12942855
Drug: Continuous trajectory
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous trajectory of psychotropic drug consumption (uninterrupted consumption during the 5-year follow-up)
Trial: 12942855
Drug: Occasional trajectory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occasional trajectory of psychotropic drug consumption (interruption of consumption for at least 1 month)
Trial: 8911887
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 mg) with grapefruit juice (250 ml)
Trial: 8911887
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 mg) with water
Trial: 6961737
Drug: Human milk
RxNorm normalized name: HUMAN MILK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human milk (1.6 g/100 kcal)
Trial: 6961737
Drug: Formula 1
RxNorm normalized name: Abena Man Formula 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula 1 (2.3 g/100 kcal)
Trial: 6961737
Drug: Formula 2
RxNorm normalized name: Formula 21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula 2 (3.0 g/100 kcal)
Trial: 31499415
Drug: sildenafil 25
RxNorm normalized name: sildenafil 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sildenafil 25 mg three times daily
Trial: 30646105
Drug: No stimulants
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No stimulants
Trial: 30646105
Drug: Long-term concurrent
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term concurrent stimulant-opioid use
Trial: 24532143
Drug: Haloperidol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 2.5 mg daily for 3 days after surgery (intervention group, n = 59)
Trial: 24532143
Drug: Haloperidol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 2.5 mg daily for 3 days after surgery (intervention group)
Trial: 17236758
Drug: Calcitriol 0.25
RxNorm normalized name: CALCITRIOL 0.25MCG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol 0.25 mcg b.i.d.
Trial: 11960538
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (n = 85) with tailored recommendations about optimizing dialysis prescriptions, expedited conversion of catheters to grafts/fistulas, and patient education.
Trial: 8559862
Drug: Inhalation anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation anesthesia with neutral phrases (color blue or yellow combined with objects ball or kite)
Trial: 344084
Drug: Trancopal (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trancopal (two tablets at night for two weeks)
Trial: 344084
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two tablets at night for two weeks)
Trial: 23819219
Drug: Ear-apex blood-letting
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ear-apex blood-letting (5-6 blood drops/time, once daily for 3 times)
Trial: 23819219
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (local application of hydrochloric levofloxacin and erycin ointment, plus local warm compress)
Trial: 11378948
Drug: Forced air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forced air warming therapy
Trial: 9009975
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (stepped plan from 1 evening injection to multiple daily injections)
Trial: 9009975
Drug: Standard insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard insulin therapy (1 injection every morning)
Trial: 26421957
Drug: Reduced-GSD patch
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-GSD patch
Trial: 26421957
Drug: Reduced-EE/GSD patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-EE/GSD patch
Trial: 12895218
Drug: Loxiglumide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide (50 mg i.v.)
Trial: 12895218
Drug: Hyoscine‐N‐butyl bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine‐N‐butyl bromide (20 mg i.v.)
Trial: 10897370
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Ivermectin and Albendazole (400 mg)
Trial: 9557072
Drug: Increased urine
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased urine cathepsin B activity (10.58 +/- 8.73 pmol AMC/mg creatinine/min)
Trial: 9557072
Drug: Increased urine
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased urine collagenase activity (8.59 +/- 4.26 pmol AMC/mg creatinine/min)
Trial: 9557072
Drug: Increased urine
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased urine excretion of fibronectin (214 +/- 335 ng/mg creatinine)
Trial: 9557072
Drug: Increased urine
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased urine excretion of TGF-beta 1 (283.55 +/- 248.13 pg/ml)
Trial: 2941573
Drug: Intravenous ketanserin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketanserin, an antagonist of S2-serotonergic receptors
Trial: 26446770
Drug: Morning administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning administration of ONO-5334 150 mg
Trial: 26446770
Drug: Evening administration
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening administration of ONO-5334 150 mg
Trial: 24395109
Drug: Dual antibody
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antibody ER assay
Trial: 24395109
Drug: Single antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single antibody ER assay
Trial: 14519486
Drug: 1% nitroprusside‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% nitroprusside‐based gel
Trial: 10958816
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (specific amino acids not detailed)
Trial: 24485216
Drug: Yearly intravenous
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yearly intravenous zoledronate (ZOL)
Trial: 16386181
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) therapy
Trial: 12021623
Drug: Phenytoin group
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin group (n = 9 patients treated with 3‐4 mg/kg/d sodium phenytoin)
Trial: 12021623
Drug: Carbamazepine group
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine group (n = 9 patients treated with 10‐20 mg/kg/d carbamazepine)
Trial: 12021623
Drug: Phenobarbital group
RxNorm normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital group (n = 5 patients treated with 1.5‐4.5 mg/kg/d phenobarbital)
Trial: 2288512
Drug: Nitrendipine, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine, 20 mg/day
Trial: 28934784
Drug: Double Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double Injection (DI) group
Trial: 28934784
Drug: Single Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Injection (SI) group
Trial: 9215339
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) infusion of amino acid solution (660 mOsm/L, pH 7) for 6 hours
Trial: 9215339
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) infusion of amino acid solution (660 mOsm/L, pH 7) for 6 hours
Trial: 3038428
Drug: Hydrochlorothiazide 15
RxNorm normalized name: hydrochlorothiazide 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 15 mg tid
Trial: 28464975
Drug: Full treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full treatment protocol (experimental condition)
Trial: 28464975
Drug: Treatment protocol
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment protocol without systematic exposure (control)
Trial: 21039358
Drug: 5.0 mg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg/ml bupivacaine
Trial: 21039358
Drug: 2.5 mg/ml
RxNorm normalized name: iodine 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/ml bupivacaine
Trial: 18495561
Drug: Pitavastatin (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin (1, 2 and 4 mg)
Trial: 17121050
Drug: Salvia miltiorrhiza
RxNorm normalized name: SALVIA MILTIORRHIZA ROOT
DrugBank: Salvia miltiorrhiza root (DB14337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvia miltiorrhiza Injection (SMI)
Trial: 17121050
Drug: Shengmai Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shengmai Injection (SI)
Trial: 11976818
Drug: Amifostine (AMF)
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amifostine (AMF) 300 mg/m2, given three times weekly for 3 weeks, followed by 2 weeks off therapy.
Trial: 11976818
Drug: Amifostine (AMF)
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amifostine (AMF) 400 mg/m2, given after initial treatment in group A.
Trial: 11976818
Drug: Amifostine (AMF)
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amifostine (AMF) 400 mg/m2 in group B, given three times weekly for 3 weeks, followed by 2 weeks off therapy.
Trial: 11976818
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow progenitor assay pre- and post-amifostine treatment in group A.
Trial: 11976818
Drug: Clonogenic assay
RxNorm normalized name: chlorogenic acid
DrugBank: Chlorogenic Acid (DB12029)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonogenic assay in group B before AMF treatment.
Trial: 11976818
Drug: Predictive power
RxNorm normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Predictive power of clonogenic assays for treatment response.
Trial: 1682905
Drug: Alfuzosin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin (2.5 mg b.i.d. up to 10 mg b.i.d.)
Trial: 1682905
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 mg b.i.d. up to 160 mg b.i.d.)
Trial: 28505954
Drug: Manipulative rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulative rehabilitation (8 sessions, 30 minutes each, twice weekly for 4 weeks)
Trial: 23187931
Drug: Local anesthesia
RxNorm normalized name: Esters of benzoic acid for local anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia and intravenous sedation
Trial: 21606413
Drug: Intermediate-dose cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intermediate-dose cytarabine (12 g/m²)
Trial: 21606413
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine (36 g/m²)
Trial: 19564837
Drug: Inactivated subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated subunit vaccine
Trial: 16960527
Drug: 6% carbohydrate-electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% carbohydrate-electrolyte solution (CES)
Trial: 11342725
Drug: Bupivacaine (0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (0.5% 10 ml, 50 mg) injected into cannula sites before incisions and 10 ml diluted with 100 ml saline into the peritoneal cavity at completion of the procedure
Trial: 9146812
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate 200 mg biweekly for 6 weeks
Trial: 2890365
Drug: Vecuronium (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.1 mg kg‐1) without priming dose (Group 1)
Trial: 2890365
Drug: Vecuronium (0.09
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.09 mg kg‐1) with priming dose of 0.015 mg kg‐1 (Group 2)
Trial: 2890365
Drug: Vecuronium (0.085
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.085 mg kg‐1) with priming dose of 0.02 mg kg‐1 (Group 3)
Trial: 2890365
Drug: Vecuronium (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.08 mg kg‐1) with priming dose of 0.02 mg kg‐1 (Group 4)
Trial: 2890365
Drug: Suxamethonium (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxamethonium (1.5 mg kg‐1) (Group 5)
Trial: 29436761
Drug: gemigliptin 50
RxNorm normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemigliptin 50 mg qd (G2)
Trial: 29436761
Drug: gemigliptin 25
RxNorm normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemigliptin 25 mg bid to 50 mg qd (G1/G2)
Trial: 29436761
Drug: sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sitagliptin 100 mg qd to gemigliptin 50 mg qd (S/G2)
Trial: 29436761
Drug: gemigliptin 50
RxNorm normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemigliptin 50 mg qd (G2/G2)
Trial: 27220310
Drug: Revascularization +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revascularization + Best Medical Therapy (BMT)
Trial: 20117319
Drug: Evidence-based guidelines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based guidelines for diagnosis and treatment of CTS
Trial: 14563967
Drug: Intrathecal urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal urokinase infusion (ITUKI therapy)
Trial: 31608799
Drug: Prasugrel 5
RxNorm normalized name: prasugrel 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 5 mg od
Trial: 30511291
Drug: Low-Dose Comparator
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-Dose Comparator (LDC) - a 60-min mindfulness introduction, referral to community and digital resources, and addition to a 6-month waitlist for MTPC.
Trial: 26115069
Drug: Intensive lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive lipid lowering treatment with 80 mg rosuvastatin loading followed by 40 mg daily
Trial: 26115069
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care group (standard statin therapy according to current guidelines)
Trial: 15719746
Drug: Zhitiaokang capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhitiaokang capsule (ZTK) for 8 weeks
Trial: 15719746
Drug: Zhibituo tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhibituo tablet (Control) for 8 weeks
Trial: 8541097
Drug: Profiles of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Profiles of progesterone through the cycle obtained from daily saliva sampling
Trial: 2172371
Drug: Dihydralazine at
RxNorm normalized name: dihydralazine
DrugBank: Dihydralazine (DB12945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydralazine at a dose of 4 micrograms/kg per min (Control)
Trial: 2172371
Drug: Perindoprilat at
RxNorm normalized name: perindoprilat
DrugBank: Perindoprilat (DB14213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindoprilat at a dose of 1 microgram/kg per min
Trial: 2172371
Drug: Perindoprilat at
RxNorm normalized name: perindoprilat
DrugBank: Perindoprilat (DB14213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindoprilat at a dose of 2.5 micrograms/kg per min
Trial: 422029
Drug: Diane (cyproteronazetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diane (cyproteronazetate 2 mg, ethinyloestradiol 50 mcg)